Promising work – an immunogenic vaccine in phase 1 trial reported just this week.
Accompanying editorial worth a read as are many of the other papers.
Promising work – an immunogenic vaccine in phase 1 trial reported just this week.
Accompanying editorial worth a read as are many of the other papers.